CYP21A2 rs72552756: Understanding Carrier Status
The rs72552756 variant is a single nucleotide polymorphism located within the CYP21A2 gene on chromosome 6. Pathogenic missense alleles at this locus are linked to 21-hydroxylase deficiency, the primary cause of autosomal recessive congenital adrenal hyperplasia. Unaffected individuals carrying one copy of the variant have a 50% chance of passing it to their offspring.
What each genotype means
Typical 21-hydroxylase function
You carry two reference copies of the CYP21A2 gene at this position, indicating that you do not have this particular variant associated with 21-hydroxylase deficiency. This genotype is associated with normal enzymatic function and does not confer carrier status for this specific congenital adrenal hyperplasia variant. However, this result does not rule out other pathogenic variants in the CYP21A2 gene or adjacent pseudogene conversions.
Carried by more than 99% of individuals across all major global populations.
Carrier of 21-hydroxylase variant
You carry one copy of the pathogenic missense variant in the CYP21A2 gene, classifying you as an asymptomatic carrier for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Carriers typically produce adequate steroid hormones and do not experience clinical symptoms, but there is a 50% probability of passing this variant to biological offspring. Reproductive risk for classic or non-classic congenital adrenal hyperplasia depends on the CYP21A2 genetic status of a reproductive partner.
Carried by fewer than 1 in 100 people across global populations, with variation depending on specific ethnic background.
Altered 21-hydroxylase activity
You carry two copies of this CYP21A2 pathogenic variant, a pattern clinically associated with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Individuals homozygous for pathogenic CYP21A2 variants typically exhibit impaired cortisol and aldosterone synthesis, with clinical severity ranging from non-classic to classic presentation. Genetic counseling and clinical evaluation are typically recommended to assess clinical expression and endocrine health.
Extremely rare in the general population, occurring in fewer than 1 in 10,000 individuals globally.
Genomic Context and the rs72552756 Variant
The single nucleotide polymorphism designated rs72552756 is located on chromosome 6 in an intricate genomic region known as the RCCX module, positioned within the CYP21A2 gene. At this position, the reference genomic sequence typically carries a guanine (G) nucleotide, while an alternative variant nucleotide is cytosine (C). Because this variant resides within a coding exon of CYP21A2, the base substitution alters an amino acid in the encoded enzyme, classifying it as a missense variant. The surrounding region on chromosome 6 presents unique challenges for standard genetic sequencing technologies because CYP21A2 is situated adjacent to a highly homologous pseudogene, CYP21A1P. This high sequence similarity frequently leads to non-allelic homologous recombination and gene conversion events, meaning accurate detection of variants like rs72552756 requires specialized clinical genomic assays.
The Biological Role of CYP21A2
The CYP21A2 gene directs the synthesis of steroid 21-hydroxylase, a member of the cytochrome P450 superfamily of heme-containing monooxygenases. This enzyme is predominantly expressed in the adrenal cortex, where it serves as a critical catalyst in the steroidogenesis pathway. Specifically, 21-hydroxylase converts progesterone into 11-deoxycorticosterone and converts 17-hydroxyprogesterone into 11-deoxycortisol. These conversions are required steps in the production of mineralocorticoids such as aldosterone, which regulates fluid and electrolyte balance, and glucocorticoids such as cortisol, which controls metabolic stress responses. Deficient 21-hydroxylase activity disrupts adrenal steroid synthesis, leading to reduced cortisol and aldosterone output alongside an accumulation of precursor hormones that are shunted into excess adrenal androgen production.
Clinical Evidence and Carrier Status
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency is inherited in an autosomal recessive pattern. Carriers who possess a single pathogenic allele at rs72552756 typically retain adequate enzyme function from their functional second allele and do not exhibit classic endocrine symptoms. Pathogenicity occurs when an individual inherits two disrupted alleles, either as a homozygote or as a compound heterozygote paired with another pathogenic CYP21A2 alteration or deletion. In public variant archives like ClinVar, certain missense changes evaluated at this position have limited or curated clinical evidence regarding exact functional severity. Because of the recessive inheritance model, carriers have a 50% probability of passing the variant allele to each child, which gains clinical relevance when paired with carrier screening of a reproductive partner.
Population Frequency and Diversity
Across large-scale reference datasets such as the Genome Aggregation Database (gnomAD) and the 1000 Genomes Project, the alternate allele associated with rs72552756 is exceptionally rare. Global population estimates place the minor allele frequency well below 0.01 (less than 1%), with the overwhelming majority of worldwide populations presenting the homozygous reference genotype. Due to the high rate of gene conversion in the HLA/RCCX region where CYP21A2 resides, variant allele distributions can fluctuate slightly among different founder populations or demographic groups. However, high-quality population counts remain difficult to resolve with standard short-read exome and genome sequencing alone, underscoring why general population databases provide limited carrier frequency estimates for complex CYP21A2 loci.
Interpreting Your Genetic Data
Identifying an alternate allele at rs72552756 in a commercial or consumer genetic test indicates carrier status rather than an active medical diagnosis. Heterozygous carriers do not manifest clinical congenital adrenal hyperplasia under standard autosomal recessive transmission. However, consumer-grade microarray genotyping and routine short-read sequencing can produce false-positive or false-negative calls in the CYP21A2 locus due to interference from the CYP21A1P pseudogene. For reproductive planning or comprehensive risk evaluation, individuals should consult a board-certified genetic counselor or medical geneticist. Clinical-grade diagnostic testing using targeted methodologies, such as multiplex ligation-dependent probe amplification (MLPA) or long-range PCR, is required to definitively establish CYP21A2 copy number and variant status.
How common is this variant?
The alternate allele at rs72552756 is exceedingly rare across diverse ancestries, with an estimated global minor allele frequency well below 0.01. Most individuals across all major reference cohorts carry the homozygous reference genotype.
Frequently asked questions
What is the difference between a carrier and someone affected by CAH?
Congenital adrenal hyperplasia is an autosomal recessive disorder, meaning an individual must inherit two non-functional copies of the gene to exhibit disease. A carrier possesses only one altered copy alongside a normal copy and generally experiences no endocrine symptoms. However, a carrier can pass the altered gene to biological offspring.
Does having the rs72552756 variant mean my child will have adrenal hyperplasia?
No, a child will only have congenital adrenal hyperplasia if they inherit a non-working CYP21A2 gene copy from both biological parents. If only one parent is a carrier, the child may also become an unaffected carrier, but will not develop the condition itself. Partner carrier screening can clarify the reproductive risk.
Can standard direct-to-consumer DNA tests accurately detect CYP21A2 variants?
Direct-to-consumer platforms often struggle to accurately resolve CYP21A2 variants because the gene is nearly identical to an adjacent pseudogene called CYP21A1P. Misalignments can lead to both false positives and missed mutations. Clinical-grade testing using specialized methods like long-range PCR or MLPA is needed to verify results.
What should I do if my genetic test indicates I carry rs72552756?
You should discuss the finding with a certified genetic counselor or physician before making any reproductive or medical decisions. A genetics specialist can order confirmatory diagnostic testing and provide guidance tailored to your family history and family planning goals.
Sources & further reading
Educational information only, last refreshed 9/14/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs72552756?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29